CanSino Biologics has developed an inhalable coronavirus vaccine that shows an increase of 250- to 300-fold in neutralizing antibody levels as a booster shot.

TOP INSIGHT
A heterologous (mix-match vaccine regimen) prime-boost regimen to increase the breadth, intensity and duration of the immune response, more than a homogeneous (same vaccine regimen) booster shot.
CanSinoBIO co-founder and chief scientific officer Zhu Tao cited a previous study conducted in Turkey whose data showed a booster dose of the mRNA vaccine widely used in Western countries for people administered along with two inactivated doses can increase the neutralising antibodies by about 25 times as compared with a booster dose of the inactivated vaccine again.
Similar clinical trial was conducted by US researchers on a heterologous booster shot regimen with three approved vaccines -- one adenovirus-based vaccine by Johnson & Johnson and two mRNA vaccines by Moderna and Pfizer. The results showed that heterologous regimen enhances immunity.
Homologous boosters increased neutralising antibody titers 4.2- to 20-fold whereas heterologous boosters increased titers 6.2- to 76-fold, said the research report published recently on pre-print server medRvix, meaning it is not yet peer-reviewed.
So far, at least 13 provinces and regions in China, such as East China's Anhui and Fujian provinces, and Central China's Hubei Province, have initiated programmes to enhance residents' immunity against Covid-19, the report said.
MEDINDIA




Email










